Revenue Growth and Raised Top-Line Guidance
Consolidated revenue of $85.9 billion, up 5.5% year-over-year. Company raised full-year consolidated revenue growth guidance to 7%–9% (from prior 5%–7%), reflecting stronger growth across reportable segments and contributions from OneOncology.
Earnings and Operating Income Expansion
Adjusted diluted EPS of $4.08 in the quarter, up 9% year-over-year. Consolidated operating income increased 12% year-over-year. Management raised full-year consolidated adjusted operating income growth guidance to 11.5%–13.5% (from 8%–10%).
US Healthcare Solutions Strength
US Healthcare Solutions revenue $76.2 billion, up 5%. US segment operating income increased 21% to $831 million, driven by specialty growth, strong health system volumes, physician practice sales, RCA contribution and early OneOncology results. Full-year US operating income guidance raised to 14%–16%.
Gross Profit and Margin Improvement
Consolidated gross profit of $3.0 billion, up 18% year-over-year. Gross profit margin improved to 3.48%, a 37 basis point increase, with RCA acquisition cited as a margin contributor.
Specialty Product Momentum (GLP-1s)
Continued strong sales in GLP-1 products, which grew by $1.0 billion or 11% versus the prior-year quarter, contributing to US segment strength.
Strategic Acquisitions and MSO Expansion
Completed acquisition of the majority of remaining equity interest in OneOncology (ownership increased from 35% to 92% with ~8% retained by practices/management) and celebrated one-year anniversary of Retina Consultants of America (RCA). OneOncology expected to be neutral to adjusted EPS in first 12 months and to be a meaningful operating income contributor thereafter.
Improving Full-Year Cash Flow Outlook
Negative adjusted free cash flow of $2.4 billion in the quarter (seasonal working capital), improved versus negative $2.8 billion prior-year quarter. Company expects full-year adjusted free cash flow of approximately $3.0 billion as working capital dynamics unwind.